Multiple patient and donor immune and malignant cell populations

The term Multiple patient and donor immune and malignant cell populations refers to a complex cellular ecosystem typically analyzed in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and adoptive cellular immunotherapies (PubMed: 32094928). This grouping encompasses the recipient's malignant cells alongside the donor's immune effector cells, such as T-cells, Natural Killer cells, and myeloid lineages (Nature Communications, 2020). It is primarily used as a descriptive category in high-dimensional research, such as single-cell transcriptomics, to map the interactions within the tumor microenvironment post-transplant (Blood, 2021). Because it represents a broad biological environment rather than a specific protein or gene, it does not function as a discrete therapeutic target for drug development. Instead, therapeutic agents like immunosuppressants or engineered CAR-T cells are designed to interact with specific molecular markers found within these various cell populations (NIH: ClinicalTrials.gov). Monitoring these populations is critical for assessing the balance between the desired graft-versus-tumor effect and the detrimental graft-versus-host disease. Ultimately, this term serves as a framework for analyzing multi-cellular responses in oncology and immunology rather than a single druggable receptor or enzyme.

Other names

Patient and donor cell subsetsTransplant immune ecosystemHeterogeneous immune and tumor cell populations

Not applicable; this term describes a heterogeneous cellular environment rather than a specific molecular target with a single mechanism of action.